Wegovy Tablets vs. Injectables: Multi-Peptide Market Trends, Brand Efficacy & Regulatory Data Analysis
Abstract: This analysis compares Wegovy tablets vs. injectables within the multi-peptide market. Injectable semaglutide demonstrates superior bioavailability (≈89%) versus oral formulations (<1%), driving dominant market share (>$12B in 2023). However, oral peptides offer enhanced patient compliance. Regulatory data shows FDA-approved injectables for obesity (Wegovy) and diabetes (Ozempic), while oral tablets (Rybelsus) remain limited to T2DM. Market trends indicate a shift toward oral delivery technologies (e.g., SNAC absorption enhancers), with a projected CAGR of 8.5% for oral GLP-1s. Brand efficacy data reveals injectables achieve 15% weight loss vs. 12% for tablets. Key selection criteria include bioavailability, dosing frequency, and regulatory certifications (GMP, FDA). Logistics require cold-chain storage (2-8°C) for injectables.